TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 and 78 with type 2 diabetes mellitus~* Patient has not been on any antihyperglycemic agent (Insulin or oral) in the last 3 months~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Patient has previously been treated with sitagliptin or has previously been in a study using a DPP-4 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sita/Met FDC (Type: EXPERIMENTAL): In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone.
- Pioglitazone (Type: ACTIVE_COMPARATOR): In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria~2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia~3. Subjects experiencing an acute exacerbation of psychotic symptoms~Exclusion Criteria:~1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~2. Subjects with a current DSM-IV-TR Axis I diagnosis of:~   * Schizoaffective disorder~  * MDD~  * Bipolar disorder~  * Delirium, dementia, amnestic or other cognitive disorder~  * Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder~3. Subjects presenting with a first episode of schizophrenia~4. Other protocol specific inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): OPC-34712 0.25 mg arm
- 2 (Type: EXPERIMENTAL): OPC-34712 low-dose arm
- 3 (Type: EXPERIMENTAL): OPC-34712 mid-dose arm
- 4 (Type: EXPERIMENTAL): OPC-34712 high-dose arm
- 5 (Type: PLACEBO_COMPARATOR): None
- 6 (Type: ACTIVE_COMPARATOR): Aripiprazole arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 18 years~* HIV infected, diagnosed with chronic hepatitis or compensated cirrhosis by hepatitis C virus (both anti-HCV antibodies and HCV RNA levels detectable in serum) not previously treated.~* Women of child-bearing age: negative pregnancy test~* Ability to understand and sign a written consent form~Exclusion Criteria:~* Previous interferon treatment~* Pregnancy or breastfeeding~* Acute or chronic hepatitis B infection (positivity for hepatitis B surface antigen or plasma DNA)~* Creatinine clearance \< 50 ml/min, according to Cockcroft-Gault~* Decompensated liver disease~* History of organ transplantation~* Concomitant treatment with immunomodulators or didanosine~* Alcohol abuse or use of other recreational drugs~* History of severe psychiatric conditions~* Autoimmune diseases~* Inability to understand and sign a written consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- G 2/3 (Type: EXPERIMENTAL): Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for elective or urgent percutaneous coronary intervention~* Who are suitable candidates for either conventional angioplasty or primary intracoronary stent implantation~* Having a target artery (native or graft) stenosis of \>= 60% (visual estimation)~Exclusion Criteria:~* Patients with acute ST-segment elevation myocardial infarction within the previous 12 hours~* With a planned staged procedure or having an unprotected left main coronary artery stenosis \> 50%~* With active internal bleeding, having a condition that may increase the risk of bleeding, or receiving ongoing treatment with an oral anticoagulant at the time of study entry~* Having had a percutaneous coronary intervention within the previous 3 months or prior intracoronary stent placement in a target vessel~* Having hypertension with systolic blood pressure \> 180 mm Hg or diastolic blood pressure \> 100 mm Hg at the time of study entry, or a platelet count \< 100,000/μL at baseline

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angioplasty With Abciximab Plus Low-Dose Heparin (Type: EXPERIMENTAL): Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
- Intracoronary Stent With Reo Pro Plus Low Dose Heparin (Type: EXPERIMENTAL): Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
- Intracoronary Stent With Placebo Plus Standard Dose Heparin (Type: PLACEBO_COMPARATOR): Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of congenital Alpha1-antitrypsin deficiency~* Must be receiving augmentation therapy with plasma-derived (human) Alpha1-Proteinase Inhibitor (Prolastin®) for at least one month prior to study entry.~* Signed written informed consent prior to initiation of any study related procedures~Exclusion Criteria:~* Females who are pregnant, breast feeding, or if of child-bearing potential, unwilling to practice adequate contraception throughout the study~* Use of systemic steroids within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).~* Subjects who have had exacerbations of their disease within one month of trial entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Alpha-1 MP (Type: EXPERIMENTAL): Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
- 2 Prolastin (Type: ACTIVE_COMPARATOR): Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy if one is needed according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings~* Patient has no clinically significant findings on a physical examination and clinical laboratory tests~* Patient meets protocol criteria for CIC: reports \< 3 bowel movements (BMs) per week and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation during the 3 months before the diagnosis with the onset at least 6 months before the diagnosis~* Patient is compliant with daily interactive voice response system (IVRS) calls~* Patient reports an average of \< 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per week by the IVRS over the 14 calendar days before the Randomization Visit and the calendar day of Randomization.~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS)~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments~* Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 μg linaclotide (Type: EXPERIMENTAL): 72 μg oral linaclotide, once daily for 12 weeks
- 145 μg linaclotide (Type: EXPERIMENTAL): 145 μg oral linaclotide, once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PAF~* Indication for CABG according to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for CABG surgery~Exclusion Criteria:~* Previous heart surgery and AF ablation procedure~* Emergency CABG~* Unstable angina or heart failure~* Persistent AF, AF at the time of screening (planned Maze procedure or pulmonary vein isolation)~* Use of I or III antiarrhythmic drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone)~* Requiring concomitant valve surgery~* Left ventricle ejection fraction \<35%~* Left atrial diameter \>55 mm~* Unwillingness to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CABG+ Botulinum toxin (Type: ACTIVE_COMPARATOR): All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH \& Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
- Control (Type: ACTIVE_COMPARATOR): All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* indication for treatment with Gilenya according label~* treatment with Gilenya intended~* no contraindications for the treatment with Gilanya~* all safety-aspects have been fullfilled~* age between 18 and 60 years~* written consent is given~Exclusion Criteria:~* relapse during the last 30 days befor randomization~* steroids within 30 days before randomization~* heart rhythm disturbance~* new or currently changed dose (last 4 weeks) of bata-blockers, calcium antagonists, antidepressants or antiarrhythmics~* diabetes mellitus~* polyneuropathy~* missing consent~* pregnancy~* lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gilenya (Type: EXPERIMENTAL): Autonomic testing during first dose adminstration of Gilenya.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TIght COntrol of Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of psoriatic arthritis by a consultant Rheumatologist with less than 24 months disease duration.~* Active disease defined by at least one tender or swollen joint or active enthesitis.~* Age ≥18 years at the time of signing the informed consent form and either male or female patients.~* Patient understands the objectives of the study and is able and willing to sign the Informed Consent Form.~* Men and women of child bearing potential (WCBP) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.~* Adequate full blood count within 28 days before randomisation:~  * Haemoglobin count \> 8.5 g/dL~ * White blood count (WBC) \> 3.5 x 10\*9/L~ * Absolute neutrophil count (ANC) \> 1.5 x 10\*9/L~ * Platelet count \> 100 x 10\*9/L~* Adequate hepatobiliary function within 28 days before randomisation:~  \*ALT and/or AST levels must be within 3 times the upper limit of normal range (ULN) for the laboratory conducting the test.~* The patient must be able to adhere to the study visit schedule and other protocol requirements.~Exclusion Criteria:~* Previous treatment for articular disease with disease modifying drugs (DMARDs) including, but not limited to, methotrexate, sulfasalazine, leflunomide,~* Women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.~* Use of any investigational agents within 4 weeks or within 5 half-lives of the investigational agent, whichever is longer, prior to randomisation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive management (Type: EXPERIMENTAL): None
- Standard management (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type I, or Type II diabetic subjects~* Subjects must have macular edema that involves the center field of the macula 3. Foveal thickness of at least 250 μm 4. Best corrected distance visual acuity in the study eye must be a letter score between 68 and 35 inclusive~Exclusion Criteria:~* Eyes with prior panretinal photocoagulation (PRP) less than 4 months prior to baseline eyes in which PRP is needed now or is likely to be needed within the next 9 months~* HbA1C level \>12% or recent signs of uncontrolled diabetes~* Atrophy/scarring/fibrosis involving the center of the macula, including evidence of laser treated atrophy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pegaptanib sodium (Type: EXPERIMENTAL): None
- sham injection (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with untreated mild-to-moderate essential hypertension, clinically diagnosed according to the World Health Organization criteria (systolic blood pressure =140-179 mm Hg and/or diastolic blood pressure =90-109 mm Hg on 3 consecutive occasions; standardized after 5 minutes in sitting position)~* Patients with newly diagnosed essential hypertension or previously treated patients from whom antihypertensive therapy can be safely withdrawn for the duration of the study.~* 18 to 65 years of age, males and non-reproductive females (surgically sterilized or post-menopausal)~* Written informed consent~* Patient is willing and able to comply with all trial requirements~Exclusion Criteria:~* Secondary hypertension~* Severe essential hypertension~* Current pharmacological treatment that could affect blood pressure~* Significant renal insufficiency \[Serum creatinine \> 159 µmol/L (\> 1.8 mg/dl)\]~* History of cerebrovascular disease~* Type 1 Diabetes or poorly controlled Type 2 Diabetes~* Body mass index (BMI) \>32~* Total cholesterol \> 6.9 mmol/L (\> 266 mg/dl)~* Triglycerides \> 3.5 mmol/L ( \> 174.3 mg/dl)~* Autoimmune diseases or severe allergies~* Patients with a history of HIV infection, AIDS, hepatitis B or C, or other immunosuppressive disorders~* Current diagnosis or a history of malignancy~* Drug or alcohol abuse within the past 2 years~* Pregnancy or breastfeeding~* Present history of mental diseases~* Participation in any drug trial within three month of onset of current trial~* Previous participation in a clinical trial with a Qb based vaccine (DerQb, NicQb, AllQb)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 100 mcg CYT006-AngQb Healthy Volunteers (Type: EXPERIMENTAL): None
- 100 mcg CYT006-AngQb Hypertensives (Type: EXPERIMENTAL): None
- 300 mcg CYT006-AngQb Hypertensives (Type: EXPERIMENTAL): None
- Placebo Healthy Volunteers (Type: PLACEBO_COMPARATOR): None
- Placebo Hypertensives (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of NASH as assessed by MRI~* Clinically documented diagnosis of T2DM~* Body mass index (BMI) \>25 kg/m2~Exclusion Criteria:~* Liver disease unrelated to NASH~* Poorly controlled T2DM or Type 1 Diabetes Mellitus~* History of alcohol or substance abuse or dependence~* Inability to undergo MRI for any reason~* History of significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 500mg HTD1801, bid (Type: EXPERIMENTAL): None
- 1000mg HTD1801, bid (Type: EXPERIMENTAL): None
- placebo, bid (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete